1. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agent;Zurenko;Antimicrob. Agents Chemother.,1996
2. Linezolid;Clemett;Drugs,2000
3. Clinical outcome (CO), safety and tolerance of linezolid (LZD) for resistant Gram-positive infections in patients with neutropenia (NPS) (Abstract);Smith;Clin. Infect. Dis.,1999
4. Zurenko GE, Todd WM, Hafkin B, Kauffman C, Bock J. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. In Program and abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 848, p. 118. American Society for Microbiology, Washington, DC.
5. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid;Gonzales;Lancet,2001